Media
This content is intended for non-U.S. journalists. U.S. journalists, please visit the U.S. Media Room
Tasigna® (nilotinib)
www.tasigna.com
(For Non U.S. Health Care Professionals Only)
TASIGNA CONTACT
Tasigna (nilotinib) is a cancer treatment for adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. Tasigna is also approved for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including imatinib.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
Tasigna Press Releases
Tasigna Images
-
May-2011
Tasigna Global First-Line Product Shot
-
-
-
Jun-2011
Tasigna Global Second-Line Product Shot
-
Tasigna Videos
Physician Soundbites
December-2011
Dr. Elias Jabbour – The University of Texas MD Anderson Cancer Center
December-2011
Dr. Hagop Kantarjian – The University of Texas MD Anderson Cancer Center
Tasigna Additional Materials
-
December-2011
Global ENESTnd 36-month Fact Sheet Infographic -
December-2011
Global Tasigna CML Fact Sheet -
December-2011
Global CML Disease Infographic -
July-2011
Global CML Treatment History Backgrounder -
July-2011
Global CML Fact Sheet
SEARCH OUR WEBSITES
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
